Skip to main content

This site is currently implementing core features and is not ready for patient use yet.

Active

InvVax

Nanoparticle vaccine developer targeting pertussis and P. aeruginosa

Manufacturers

Country
Czechia
Founded
HQ City
HQ Address
Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1RQ, United Kingdom
Email
Phone

About

InvVax develops nanoparticle vaccines targeting pertussis (whooping cough) and Pseudomonas aeruginosa lung infections, utilizing novel antigen display technologies.

Vaccines

No data available

FAQ

No FAQ items available.